Ardelyx (ARDX) Net Equity Issued and Repurchased (2013 - 2023)
Ardelyx's (ARDX) quarterly Net Equity Issued and Repurchased came in at -$12000.0 in Q4 2023, down 100.06% YoY from $18.8 million in Q4 2022, and down 100.02% on a QoQ basis from $58.4 million in Q3 2023.
Ardelyx (ARDX) Net Equity Issued and Repurchased (2013 - 2023) Analysis & Trends
Ardelyx (ARDX) has 8 years of Net Equity Issued and Repurchased data on file, last reported at -$12000.0 in Q4 2023.
- Quarterly Net Equity Issued and Repurchased fell 100.06% year-over-year to -$12000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$12000.0 (down 100.01% YoY) and the FY2023 annual result came in at $119.2 million, up 66.47% from the prior year.
- Net Equity Issued and Repurchased slipped to -$12000.0 in Q4 2023, from $58.4 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $134.9 million in Q4 2019 to a low of -$12000.0 in Q4 2023.
- A 5-year average of $33.2 million and a median of $23.3 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 776.54% in 2023, down 100.06% in 2023.
- Tracing ARDX's Net Equity Issued and Repurchased over 5 years: stood at $134.9 million in 2019, then tumbled by 83.91% to $21.7 million in 2020, then climbed by 15.21% to $25.0 million in 2021, then slipped by 24.88% to $18.8 million in 2022, then plunged by 100.06% to -$12000.0 in 2023.
- The last three Net Equity Issued and Repurchased figures came in at -$12000.0 (Q4 2023), $58.4 million (Q3 2023), and $11.6 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -12,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | 58.40 Mn |
| Sep 30, 2023 | 58.40 Mn |
| Jun 30, 2023 | 11.60 Mn |
| Jun 30, 2023 | 11.60 Mn |
| Mar 31, 2023 | 51.90 Mn |
| Mar 31, 2023 | 51.90 Mn |
| Dec 31, 2022 | 18.78 Mn |
| Dec 31, 2022 | 18.78 Mn |
| Sep 30, 2022 | 35.10 Mn |
| Sep 30, 2022 | 35.10 Mn |
| Jun 30, 2022 | 12.56 Mn |
| Jun 30, 2022 | 12.56 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Mar 31, 2022 | 5.92 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Sep 30, 2021 | 4.74 Mn |
| Sep 30, 2021 | 4.74 Mn |